ReviewNature reviews. Clinical oncology2010
The role of SRC-3 in human breast cancer.
Review in Nature reviews. Clinical oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 55 citations in OpenAlex.
- Integrated profiling identifies NCOA3 as a prognostic factor in patients with glioma.Functional & integrative genomics · 2026Article
- Steroid receptor coactivators: from basic research to translational opportunities.Endocrine reviews · 2026Review
- Steroid receptor coactivators in immunity - From function to emerging translational opportunities.The Journal of biological chemistry · 2026Review
- Many faces of mammalian NSD methyltransferases.Cellular & molecular biology letters · 2026Review
- NCOA3 knockdown delays human embryo development.Heliyon · 2024Article
- Lead Compound Development of SRC-3 Inhibitors with Improved Pharmacokinetic Properties and Anticancer Efficacy.Journal of medicinal chemistry · 2024Article
- Critical Roles of SRC-3 in the Development and Progression of Breast Cancer, Rendering It a Prospective Clinical Target.Cancers · 2023Review
- Targeting Triple-Negative Breast Cancer by the Phytopolyphenol Carnosol: ROS-Dependent Mechanisms.Antioxidants (Basel, Switzerland) · 2023Review
- Significant Association of Estrogen Receptor-β Isoforms and Coactivators in Breast Cancer Subtypes.Current issues in molecular biology · 2023Article
- Targeting phase separation on enhancers induced by transcription factor complex formations as a new strategy for treating drug-resistant cancers.Frontiers in oncology · 2022Review
- Estrogen Receptor Alpha and ESR1 Mutations in Breast Cancer.Advances in experimental medicine and biology · 2022Article
- SRC-3, a Steroid Receptor Coactivator: Implication in Cancer.International journal of molecular sciences · 2021Review
- A genome-scale CRISPR Cas9 dropout screen identifies synthetically lethal targets in SRC-3 inhibited cancer cells.Communications biology · 2021Article
- The Biological Significance of Targeting Acetylation-Mediated Gene Regulation for Designing New Mechanistic Tools and Potential Therapeutics.Biomolecules · 2021Review
- Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma.Nature communications · 2021Article
- Carnosol Is a Novel Inhibitor of p300 Acetyltransferase in Breast Cancer.Frontiers in oncology · 2021Article
- Phosphorylation of steroid receptor coactivator-3 (SRC-3) at serine 857 is regulated by the p38Scientific reports · 2020Article
- A potential target for liver cancer management, lysophosphatidic acid receptor 6 (LPAR6), is transcriptionally up-regulated by the NCOA3 coactivator.The Journal of biological chemistry · 2020Article
- Metabolic Dysregulation Controls Endocrine Therapy-Resistant Cancer Recurrence and Metastasis.Endocrinology · 2019Review
- Differential microRNA expression profiles determined by next-generation sequencing in three fulvestrant-resistant human breast cancer cell lines.Oncology letters · 2019Article
Corrections and comments
- Erratum issuedCoombes, Charles R [corrected to Coombes, R Charles]
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
Members of the nuclear receptor superfamily are ligand-regulated transcription factors involved in the control of a broad range of normal physiological and disease processes. The estrogen receptor alpha (ERalpha) is a member of the steriod receptor family, which is part of the nuclear receptor superfamily. ERalpha it is important for many biological processes and plays a key role in the pathogenesis of breast cancer. Gene regulation by ERalpha requires the recruitment of a multitude of transcriptional co-regulators to the promoters of estrogen-responsive genes. There is evidence in support of the involvement of these co-regulators in breast cancer progression. We review the role of steroid receptor co-activator-3 (SRC-3), which is frequently amplified in breast cancer, and its role in breast cancer risk, outcome and response to endocrine therapy in patients with breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.